EGFR and non-small cell lung carcinoma: Although the clinical use of EGFR tyrosine kinase inhibitors (EGFR-TKIs) may improve the prognosis of patients with NSCLC, most patients exhibit resistance to EGFR-TKIs due either to genetic endowments [7] or acquired resistance after long-term chemotherapy.